NFYC and cancer: Although, in current experimental settings, it is difficult to distinguish which effect is dominant or whether BIRC6 is directly responsible for this inhibitory effect through autophagy, all the above results suggest the importance of NFYC-AS1 as a pro-cancer factor in LUAD patients.